Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q4 EPS of $0.35, $0.46 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $83.4 million versus the consensus estimate of $72.36 million.

Financial Guidance:

Kiniksa expects 2024 ARCALYST net product revenue of between $360 million and $380 million.
Kiniksa expects that its cash, cash equivalents, and short-term investments will fund its current operating plan into at least 2027.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.